Biomarkers: what are they and how are they useful in the diagnosis and treatment of prostate cancer? On this episode of the JNM Podcast, our panel of experts explores what they call a "liquid biopsy:" using biomarkers shed by cancer cells into the bloodstream to gain vital insights about the disease and its progression, identify candidates who would benefit from certain therapies, and monitor the effectiveness of treatments. Listen now to learn more about the clinical use of biomarkers. Our h...
Is it really happening? Astatine-211 is a promising new radionuclide being further developed and researched for the treatment of cancer. It is a short half-life alpha-emitter that's attracting more interest from the nuclear medicine community as investors take notice of its potential and production capacity improves. So where will 211At be by 2030? And is this a radionuclide that could show up in a clinical setting in the near future? Join host Ken Herrmann, MD with guests Brenda Sandmaier, M...
In this live episode of The JNM Podcast, Johannes Czernin interviews Anna Karmann to talk about the various career trajectories available in nuclear medicine.
The JNM Podcast is back and live from New Orleans. Guests David Mankoff, Hossein Jadvar, and Todd Peterson answer the question: "Can society-based journals compete with corporate-based publications?"
You love the column, now hear it in person! Throughout the meeting, JNM Editor in Chief Johannes Czernin will host Discussions with Leaders to talk about the most important and exciting topics in nuclear medicine. First up is Richard Wahl, MD.
Standardized uptake values (SUV) measure a patient's response to nuclear medicine therapy. But what other markers of success are there, and do these markers and the interpretation of them vary depending on the disease being imaged? Sally Barrington, MD, works specifically on lymphoma and shares her expertise on what markers of success and criteria are critical to her in understanding patients' responses to treatment. Joining her, along with our host Ken Herrmann, MD, are Louise Emmett, ...
Is PSMA becoming so regularly used that it's...boring? Not according to this lively discussion. Join us for episode 9 of the JNM Podcast, where host Ken Herrmann discusses the state of PSMA PET with experts Thomas Hope, Oliver Sartor, and Wolfgang Fendler. The panel talks about PSMA PET in clinical trials vs. real-life disease management, appropriate use criteria and its evolution, and patient and treatment data. Plus, what's next for PSMA as it matures into adulthood? Tune in to find out! Th...
The JNM Podcast is back in 2025! Join Ken Herrmann, MD, and co-moderator Frank Bengel, MD, for an episode on cardiovascular perfusion imaging. In the U.S., SPECT imaging makes up five to six million studies per year. But PET studies make up just 2.2 million, and only 7%, or 150,000 of those, are cardiac PET imaging. But that may be about to change. The FDA has recently approved Flurpiridaz F-18, which may make cardiac imaging more accessible to patients across the country. Here to discuss the...
Get ready for an episode that's a bit...meta. In Episode 7, our host Ken Herrmann is joined by the podcasters behind GU Cast: Declan Murphy, FRACS, FRCS, and Renu Eapen, MBBS, FRACS. Together with Wolfgang Weber, MD, PhD, they discuss how social media has shaped the landscape of medicine - from how we get medical news, to sharing new research to interacting with colleagues and patients. Tune in now! Thanks to Sofie Biosciences for sponsoring this episode! https://sofie.com/
Join us for episode 6 of the JNM podcast. Moderator Ken Herrmann, MD is joined by Simron Singh, MD and Lisa Bodei, MD, PhD to discuss NETTER-2. NETTER-2 was the first trial to examine radioligand therapy as a first-line therapy for cancers, as opposed to waiting until later stages. Our panelists discuss the results of this trial and its implications for patients. Thank you to SOFIE Biosciences for sponsoring this episode. https://sofie.com/
Radioligand therapy (RLT) targets cancer cells with radiation while minimizing impact on surrounding healthy tissue. In this episode of JNM Podcast, our panelists discuss training, access, production capacity, and everything else that is necessary to make RLT more widely available to the patients who need it. Moderator: Ken Herrmann, MD (Universitätsmedizin, Essen, Germany). Panelists: Andrei Iagaru, MD (Stanford University Medical Center, Stanford, California), Leonhard Schaetz (Novart...
The VISION Trial is the first-in-its-field study to use radiopharmaceuticals that directly target prostate cancer tumors. Hear from one of the lead researchers on this ground-breaking study as he discusses how the trial has opened up a completely new field of study in prostate cancer research and shaped the future of nuclear medicine therapy in combatting the disease. Join us for Episode 4 of JNM Podcast from The Journal of Nuclear Medicine. Moderators: Ken Herrmann, MD (Universitätsmedizin,...
This month's episode of the JNM Podcast takes the discussion of Pb-212 worldwide! Researchers from the UK, Australia, and North America discuss the logistics of using lead-212 as a radionuclide imaging agent. From availability to production to transportation, Pb-212 presents both great opportunities and great challenges. Moderator Ken Herrmann, MD, leads this intercontinental panel in a discussion about other radionuclides and their pros and cons. He's joined by David Bauer, PhD, from Memoria...
The Journal of Nuclear Medicine presents a new podcast on advances in dementia imaging. Panelists discuss the importance of amyloid and tau PET imaging in dementia diagnosis and treatment, highlighting their roles in clinical trials and future therapies. They emphasize the significance of early detection and the potential for personalized medicine approaches. Panel: • Ken Herrmann, MD, MBA (Universitätsmedizin, Essen, Germany) • Henryk Barthel, MD, PhD (Leipzig University) • Gil Rabinov...
The Journal of Nuclear Medicine presents a new podcast on FAPI-directed theranostics for cancer diagnosis and treatment. Join moderator Ken Herrmann (Universitätsmedizin) and panelists Andrew Scott (Austin Health), Katharina Lückerath (Universitätsmedizin) and Shadi Esfahadi (Mass General Hospital) as they delve into the history of FAP, discuss challenges, and predict the pathway to clinical success. #JNuclMed #NuclearMedicine #FAPI #Theranostics